STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMAX
  4. [Form 4] IMAX CORP Insider Trading Activity

IMAX (NYSE: IMAX) CEO sells stock in 3-day trading-plan sale

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

IMAX CORP (IMAX) reported insider transactions by Chief Executive Officer Richard L. Gelfond involving option exercises and share sales executed under a Rule 10b5-1 trading plan dated May 19, 2026. On August 18 and 19, 2026, he converted stock options into a total of 356,757 common shares at an exercise price of $31.90 per share and sold the converted shares in open-market transactions. He also sold an additional 100,000 common shares on August 20, 2026.

Following these transactions, Mr. Gelfond’s aggregate remaining holdings are disclosed as 975,654 stock options, 231,562 restricted share units, and 665,002 common shares.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider GELFOND RICHARD L
Role Chief Executive Officer
Sold 456,757 shs ($23.98M)
Approx. gross sale proceeds $23.98M
Approx. exercise cost $11.38M
Type Security Shares Price Value
Sale common shares 100,000 $53.2337 $5.32M
Conversion stock options (to buy) F3, F4, F5 205,504 $31.90 $6.56M
Conversion common shares F1 205,504 $31.90 $6.56M
Sale common shares F2 205,504 $53.2656 $10.95M
Conversion stock options (to buy) F3, F4, F5 151,253 $31.90 $4.82M
Conversion common shares F1 151,253 $31.90 $4.82M
Sale common shares F2 151,253 $51.0049 $7.71M
holding common shares (opening balance) -- -- --
Holdings After Transaction: stock options (to buy) — 975,654 shares (Direct); common shares — 665,002 shares (Direct); common shares (opening balance) — 765,002 shares (Direct)
Footnotes (5)
  1. F1. Represents the conversion upon exercise of stock options into common shares pursuant to a 10b5-1 Plan dated May 19, 2026.
  2. F2. Represents the sale of converted common shares pursuant to a 10b5-1 Plan dated May 19, 2026.
  3. F3. These options were issued in 2017 and are set to expire on January 3, 2027.
  4. F4. The stock options became exercisable in nine installments: 39,640 on each of May 1, 2017, September 1, 2017, May 1, 2018, December 31, 2018, September 1, 2019 and December 31, 2019, and 39,639 on each of December 31, 2017, September 1, 2018 and May 1, 2019.
  5. F5. This represents the number of common shares for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 975,654, 231,562 and 665,002, respectively.
Shares sold 456,757 common shares Total net shares sold across reported transactions
Shares sold 2026-08-18 151,253 common shares at $51.0049 per share Open-market sale on August 18, 2026
Shares sold 2026-08-19 205,504 common shares at $53.2656 per share Open-market sale on August 19, 2026
Shares sold 2026-08-20 100,000 common shares at $53.2337 per share Open-market sale on August 20, 2026
Options exercised 356,757 shares at $31.90 per share Total shares from option conversions in August 2026
Remaining options 975,654 stock options Options outstanding after these transactions
Remaining RSUs 231,562 restricted share units RSU balance after these transactions
Remaining common shares 665,002 common shares Common share holdings after these transactions
Rule 10b5-1 Plan regulatory
"pursuant to a 10b5-1 Plan dated May 19, 2026"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Conversion of derivative security financial
"transaction_code_description: Conversion of derivative security"
restricted share unit financial
"remaining outstanding option, restricted share unit and common share balances"
A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.
stock options financial
"These options were issued in 2017 and are set to expire"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
open market or private transaction financial
"transaction_code_description: Sale in open market or private transaction"

FAQ

What did IMAX (IMAX) CEO Richard Gelfond report in this Form 4?
He reported exercising stock options into 356,757 common shares at $31.90 per share and selling those shares plus an additional 100,000 common shares in open-market transactions, all under a Rule 10b5-1 plan dated May 19, 2026.

How many IMAX (IMAX) shares did the CEO sell and at what prices?
Richard Gelfond reported selling 456,757 common shares in total, including 151,253 shares at $51.0049, 205,504 shares at $53.2656, and 100,000 shares at $53.2337 per share in open-market transactions.

What options did the IMAX (IMAX) CEO exercise in this filing?
He converted stock options for 356,757 shares with an exercise price of $31.90 per share. These options were issued in 2017 and are scheduled to expire on January 3, 2027, with vesting having occurred in multiple installments between 2017 and 2019.

Were the IMAX (IMAX) insider transactions under a Rule 10b5-1 plan?
Yes. The filing indicates the transactions were made under a Rule 10b5-1 trading plan dated May 19, 2026, and the related footnotes specify that both the option exercises and the sale of converted common shares were pursuant to that plan.

What are Richard Gelfond’s remaining IMAX (IMAX) equity holdings after these trades?
After the reported transactions, Richard Gelfond’s aggregate remaining holdings are 975,654 stock options, 231,562 restricted share units, and 665,002 common shares, as disclosed in the filing footnotes for this Form 4.

When do the IMAX (IMAX) CEO’s exercised options expire?
The options exercised in these transactions were issued in 2017 and are scheduled to expire on January 3, 2027, according to the footnotes describing the option grant and its terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GELFOND RICHARD L
(Last)(First)(Middle)
902 BROADWAY
20TH FLOOR
(Street)
NEW YORK NEW YORK 10010-6002
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
IMAX CORP [ IMAX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
common shares (opening balance)765,002D
common shares08/18/2026C151,253(1)A$31.9916,255D
common shares08/18/2026S151,253(2)D$51.0049765,002D
common shares08/19/2026C205,504(1)A$31.9970,506D
common shares08/19/2026S205,504(2)D$53.2656765,002D
common shares08/20/2026S100,000D$53.2337665,002D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
stock options (to buy)(3)$31.908/18/2026C151,253 (4)01/03/2027common shares151,253$31.91,181,158(5)D
stock options (to buy)(3)$31.908/19/2026C205,504 (4)01/03/2027common shares205,504$31.9975,654(5)D
Explanation of Responses:
1. Represents the conversion upon exercise of stock options into common shares pursuant to a 10b5-1 Plan dated May 19, 2026.
2. Represents the sale of converted common shares pursuant to a 10b5-1 Plan dated May 19, 2026.
3. These options were issued in 2017 and are set to expire on January 3, 2027.
4. The stock options became exercisable in nine installments: 39,640 on each of May 1, 2017, September 1, 2017, May 1, 2018, December 31, 2018, September 1, 2019 and December 31, 2019, and 39,639 on each of December 31, 2017, September 1, 2018 and May 1, 2019.
5. This represents the number of common shares for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 975,654, 231,562 and 665,002, respectively.
Remarks:
/s/ Richard L. Gelfond08/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR